Hemagen (US) gets Chagas approval:
This article was originally published in Clinica
Hemagen (US) has received FDA approval to market its Chagas' disease ELISA. Chagas' disease, a progressively debilitating, insect-borne parasitic disease, can be transmitted through blood transfusions and usually kills its victims within ten years. Testing is routine in Latin American blood banks, but not in the US. The test is already marketed in South America by German major Boehringer Mannheim (see Clinica No 583, p 3), and in Brazil under Hemagen's own label. As many as 7% of the South American population have Chagas' disease.